Related Experiment Video
Updated: Apr 30, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Trametinib
1Department of Hematology and Oncology, Freiburg University Medical Center, Albert Ludwigs University, Hugstetterstr. 55, 79106, Freiburg, Germany, robert.zeiser@uniklinik-freiburg.de.
Abstract:
The mitogen-activated protein kinase (MEK MAPK/ERK kinase) signaling pathways play a critical role in regulation of diverse cellular activities, including survival, differentiation, proliferation, motility, and angiogenesis. Therefore, MEK inhibition was recognized as a promising target for antineoplastic therapy. While multiple MEK inhibitors have been tested clinically only trametinib (GSK1120212), an oral MEK inhibitor which is selective for MEK1 and MEK2 has shown promising activity in several clinical trials on melanoma and colorectal cancer and it is being evaluated by the FDA for the treatment of metastatic melanoma. Mechanistically it was shown that trametinib induces cell cycle arrest in vitro. In this overview, important preclinical and clinical data for trametinib are presented including mechanism-based in vitro studies as well as findings from different clinical studies. Future clinical trial in different solid tumor entities will define the therapeutic role of this targeted therapy approach, possibly as a combination with other targeted therapies such as BRAF inhibitors.
Insights
Trametinib, a selective MEK inhibitor, shows promise in treating metastatic melanoma and colorectal cancer by inducing cell cycle arrest. Further trials will define its role in solid tumors, potentially combined with other targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Mitogen-activated protein kinase (MEK) signaling pathways regulate crucial cellular functions like proliferation and survival.
- MEK inhibition is a key strategy in antineoplastic therapy.
- Trametinib is a selective oral inhibitor of MEK1 and MEK2.
Purpose of the Study:
- To review preclinical and clinical data for trametinib.
- To highlight trametinib's efficacy in melanoma and colorectal cancer.
- To discuss trametinib's mechanism of action and future therapeutic potential.
Main Methods:
- Review of preclinical in vitro studies.
- Analysis of clinical trial data.
- Examination of trametinib's mechanism of action, including cell cycle arrest.
Main Results:
- Trametinib demonstrates promising activity in clinical trials for melanoma and colorectal cancer.
- Trametinib selectively inhibits MEK1 and MEK2.
- In vitro studies show trametinib induces cell cycle arrest.
Conclusions:
- Trametinib is a promising targeted therapy for metastatic melanoma, with FDA evaluation underway.
- Further clinical trials are needed to establish trametinib's role in various solid tumors.
- Combination therapy with agents like BRAF inhibitors may enhance trametinib's therapeutic efficacy.
More Related Videos
04:36Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:15Anthelminthic Agents
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...